MeSH term
Frequency | Condition_Probility | Comparative Study | 30 | 0.0 |
English Abstract | 25 | 0.0 |
Female | 162 | 0.0 |
Humans | 204 | 0.0 |
Male | 60 | 0.0 |
Middle Aged | 42 | 0.0 |
Graft Survival | 2 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Prospective Studies | 6 | 0.0 |
Adult | 62 | 0.0 |
Lung Transplantation/*adverse effects | 2 | 40.0 |
Prognosis | 2 | 0.0 |
Retrospective Studies | 9 | 0.0 |
Treatment Failure | 2 | 0.0 |
Adolescent | 13 | 0.0 |
Incidence | 3 | 0.0 |
Lung Transplantation/*adverse effects/methods | 2 | 100.0 |
Age Factors | 4 | 0.0 |
Child | 6 | 0.0 |
Child, Preschool | 4 | 0.0 |
Graft Rejection | 2 | 1.0 |
Infant | 5 | 0.0 |
Reoperation | 3 | 2.0 |
Risk Factors | 5 | 0.0 |
Survival Analysis | 4 | 0.0 |
Transplantation, Homologous | 2 | 0.0 |
Treatment Outcome | 5 | 0.0 |
6-Ketoprostaglandin F1 alpha/blood | 3 | 16.0 |
Abdomen/surgery | 2 | 14.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Inflammation/*physiopathology | 2 | 3.0 |
Research Support, Non-U.S. Gov't | 85 | 0.0 |
Time Factors | 23 | 0.0 |
Androstenedione/metabolism | 3 | 10.0 |
Animals | 75 | 0.0 |
Cattle/*physiology | 2 | 25.0 |
Estradiol/metabolism | 3 | 3.0 |
Ovulation | 5 | 9.0 |
Progesterone/metabolism | 5 | 6.0 |
Aged | 17 | 0.0 |
Prostaglandins F/secretion | 4 | 100.0 |
Dinoprost/metabolism | 2 | 18.0 |
Dinoprostone/metabolism | 2 | 2.0 |
Macaca mulatta | 2 | 0.0 |
Ovulation/*physiology | 2 | 10.0 |
Prostaglandins/*biosynthesis | 23 | 50.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 56 | 0.0 |
Estrus | 2 | 18.0 |
Gonadotropins/*pharmacology | 3 | 17.0 |
Menstrual Cycle | 2 | 1.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Base Sequence | 4 | 0.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Rats | 12 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Pregnancy | 60 | 0.0 |
Prostaglandins F/biosynthesis | 16 | 94.0 |
Radioligand Assay | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Tissue Donors | 2 | 0.0 |
Cattle | 6 | 0.0 |
Chorionic Gonadotropin/*pharmacology | 4 | 7.0 |
*Postpartum Period | 2 | 5.0 |
Fertilization/*physiology | 2 | 16.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Estradiol/blood | 4 | 0.0 |
Horses/*metabolism | 2 | 40.0 |
Progesterone/blood | 8 | 3.0 |
Cloning, Molecular | 2 | 0.0 |
Prostaglandins/*biosynthesis/physiology | 2 | 66.0 |
Signal Transduction | 2 | 0.0 |
Dogs | 3 | 0.0 |
Species Specificity | 2 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Gastrointestinal Motility/*drug effects | 2 | 9.0 |
Mice | 12 | 0.0 |
Cardiopulmonary Bypass | 2 | 4.0 |
Sex Factors | 2 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Chorionic Gonadotropin/pharmacology | 10 | 7.0 |
Prostaglandins F/analysis | 6 | 66.0 |
Radioimmunoassay | 19 | 1.0 |
Cats | 3 | 0.0 |
Haplorhini | 2 | 0.0 |
Rabbits | 9 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Cyclic AMP/physiology | 3 | 2.0 |
Gonadotropins, Equine/pharmacology | 3 | 14.0 |
Ovary/*physiology | 2 | 5.0 |
Progesterone/*blood | 3 | 7.0 |
*Intercellular Signaling Peptides and Proteins | 11 | 2.0 |
Spirometra/*physiology | 2 | 100.0 |
Body Weight/physiology | 2 | 2.0 |
Substrate Specificity | 3 | 0.0 |
Binding, Competitive | 5 | 0.0 |
Isoelectric Focusing | 2 | 0.0 |
Molecular Weight | 3 | 0.0 |
Culture Techniques | 8 | 1.0 |
Prostaglandins/*secretion | 4 | 80.0 |
Prostaglandins E/secretion | 4 | 80.0 |
Cells, Cultured | 12 | 0.0 |
Dinoprost/*secretion | 2 | 100.0 |
Dinoprostone/*secretion | 2 | 33.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Endometrium/*secretion | 2 | 40.0 |
Kinetics | 7 | 0.0 |
*Luteal Phase | 2 | 9.0 |
Stromal Cells/metabolism | 2 | 2.0 |
Cattle/*growth & development/immunology/physiology | 2 | 100.0 |
Immunization, Secondary/veterinary | 3 | 100.0 |
Vaccination/*veterinary | 3 | 60.0 |
Prostaglandins F/*blood | 12 | 80.0 |
Cell Division/drug effects | 2 | 0.0 |
Endometrium/*metabolism | 4 | 4.0 |
Estradiol/pharmacology | 7 | 2.0 |
Antibody Formation | 2 | 0.0 |
Dinoprost/*immunology | 2 | 50.0 |
Random Allocation | 3 | 0.0 |
Cattle/immunology/*physiology | 2 | 100.0 |
Estrus/*immunology | 2 | 66.0 |
Growth Substances/*pharmacology | 6 | 1.0 |
6-Ketoprostaglandin F1 alpha/biosynthesis | 4 | 22.0 |
Hysterectomy | 4 | 5.0 |
Prostaglandins E/biosynthesis | 13 | 56.0 |
Thromboxane B2/biosynthesis | 4 | 17.0 |
Calcium/physiology | 2 | 0.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Nordihydroguaiaretic Acid/pharmacology | 2 | 9.0 |
Quinacrine/pharmacology | 2 | 13.0 |
In Vitro | 24 | 0.0 |
Myometrium/drug effects/*metabolism | 2 | 33.0 |
Prostaglandin Antagonists/pharmacology | 2 | 12.0 |
Prostaglandins/*pharmacology | 2 | 8.0 |
Uterine Contraction/drug effects | 5 | 35.0 |
Decidua/*metabolism | 2 | 5.0 |
6-Ketoprostaglandin F1 alpha/metabolism | 3 | 20.0 |
Arachidonic Acids/*metabolism | 2 | 6.0 |
Follicular Phase | 4 | 8.0 |
Progesterone/*metabolism | 2 | 5.0 |
Prostaglandins F/metabolism | 4 | 80.0 |
Thromboxane B2/metabolism | 2 | 9.0 |
17-alpha-Hydroxyprogesterone | 2 | 4.0 |
Hydroxyprogesterones/metabolism | 2 | 50.0 |
Indomethacin/*pharmacology | 4 | 10.0 |
Ovulation/*drug effects | 2 | 13.0 |
Ovulation Induction | 2 | 5.0 |
Prostaglandins E/metabolism | 4 | 33.0 |
Rats, Inbred Strains | 8 | 1.0 |
Steroids/*metabolism | 2 | 5.0 |
Testosterone/metabolism | 2 | 1.0 |
Estradiol/*metabolism | 2 | 3.0 |
Prostaglandins/*metabolism | 5 | 38.0 |
Sheep | 3 | 0.0 |
Swine | 6 | 0.0 |
Progesterone/pharmacology | 3 | 2.0 |
Prostaglandins/*physiology | 4 | 17.0 |
Renin/blood | 3 | 0.0 |
Oxytocin/*pharmacology | 2 | 11.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Epinephrine/pharmacology | 3 | 3.0 |
Indomethacin/pharmacology | 10 | 4.0 |
Cesarean Section | 7 | 11.0 |
Labor, Obstetric/physiology | 2 | 28.0 |
Microscopy, Electron | 2 | 0.0 |
Abortion, Induced/*methods | 3 | 37.0 |
Double-Blind Method | 3 | 0.0 |
Pregnancy Trimester, Second | 5 | 2.0 |
Growth Substances/*physiology | 3 | 2.0 |
Infant, Newborn | 6 | 0.0 |
Prostaglandins E/*analysis | 6 | 85.0 |
Prostaglandins F/*analysis | 7 | 100.0 |
Semen/*analysis | 4 | 28.0 |
*Sperm Count | 2 | 18.0 |
*Sperm Motility | 2 | 8.0 |
Growth Hormone/pharmacology | 3 | 8.0 |
Larva | 2 | 6.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Cell Line | 5 | 0.0 |
Prostaglandins E/analysis | 5 | 55.0 |
Adipose Tissue/drug effects/*metabolism | 2 | 12.0 |
Cestoda/*analysis | 2 | 100.0 |
Glucose/metabolism | 2 | 0.0 |
Spirometra/*analysis | 2 | 100.0 |
Corpus Luteum/*metabolism | 3 | 16.0 |
Luteal Phase | 4 | 6.0 |
Arachidonic Acids/pharmacology | 6 | 18.0 |
*Dinoprost/*analogs & derivatives | 14 | 73.0 |
*Dinoprostone/*analogs & derivatives | 4 | 80.0 |
Prostaglandins E/*pharmacology | 5 | 35.0 |
Prostaglandins F/*pharmacology | 5 | 71.0 |
Chromatography, Affinity | 2 | 0.0 |
Growth Substances/*isolation & purification | 2 | 18.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Dinoprostone | 12 | 17.0 |
*Labor, Induced | 7 | 53.0 |
Uterine Contraction/*drug effects | 3 | 42.0 |
Cross Reactions | 2 | 0.0 |
Organ Size/drug effects | 3 | 3.0 |
Amniotic Fluid/metabolism | 2 | 6.0 |
Arachidonic Acid | 7 | 10.0 |
Dinoprost | 18 | 52.0 |
Labor Complications/*metabolism | 3 | 75.0 |
Prostaglandins F/*biosynthesis | 12 | 100.0 |
Cell Separation | 2 | 0.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Prostaglandins E/*metabolism | 7 | 58.0 |
Prostaglandins F/*metabolism | 9 | 90.0 |
Amniotic Fluid/*metabolism | 2 | 5.0 |
*Labor, Obstetric | 5 | 21.0 |
Oxytocin/*blood | 2 | 12.0 |
Fallopian Tubes/*drug effects | 3 | 100.0 |
Prostaglandins E/pharmacology | 3 | 11.0 |
Prostaglandins F/pharmacology | 6 | 42.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Uterine Contraction | 2 | 22.0 |
*Cestoda | 2 | 100.0 |
*Spirometra | 2 | 100.0 |
Prostaglandins/*analysis | 4 | 80.0 |
Reference Values | 3 | 0.0 |
Clinical Trials | 3 | 0.0 |
Muscle Contraction/drug effects | 6 | 6.0 |
Gestational Age | 4 | 0.0 |
Glucose/*metabolism | 2 | 1.0 |
Receptors, Prolactin | 2 | 10.0 |
Neoplasm Metastasis | 3 | 0.0 |
Molecular Conformation | 2 | 0.0 |
Prostaglandin D2 | 2 | 40.0 |
Guinea Pigs | 4 | 0.0 |
Blood Pressure/drug effects | 6 | 1.0 |
Ovary/*metabolism | 3 | 5.0 |
Fibroblasts | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Gallbladder/*metabolism | 2 | 15.0 |
Prostaglandins E/*biosynthesis | 8 | 50.0 |
Amniotic Fluid/*analysis | 4 | 5.0 |
Arachidonic Acids/metabolism | 3 | 7.0 |
Chromatography, Gel | 2 | 0.0 |
Estrone/blood | 2 | 2.0 |
Uterus/*physiology | 2 | 16.0 |
*Alprostadil/*analogs & derivatives | 3 | 100.0 |
Hypertension/*metabolism | 2 | 6.0 |
Thromboxane B2/blood | 2 | 5.0 |
Labor, Obstetric | 11 | 25.0 |
*Pregnancy | 6 | 4.0 |
Oxytocin/pharmacology | 2 | 18.0 |
Granulosa Cells/*metabolism | 2 | 5.0 |
Theca Cells/*metabolism | 2 | 50.0 |
Decidua/metabolism | 6 | 21.0 |
Infusions, Parenteral | 3 | 2.0 |
Myometrium/metabolism | 4 | 17.0 |
Amnion/metabolism | 2 | 12.0 |
Placenta/*metabolism | 3 | 1.0 |
Organ Culture Techniques | 4 | 1.0 |
Amnion/*metabolism | 3 | 23.0 |
Contraceptives, Oral/*pharmacology | 2 | 9.0 |
*Menstruation | 4 | 10.0 |
Placenta/*physiology | 2 | 7.0 |
Prostaglandins/*blood | 10 | 66.0 |
Prostaglandins E/blood | 9 | 64.0 |
Prostaglandins F/blood | 10 | 90.0 |
Veins | 3 | 5.0 |
Menstruation | 4 | 6.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
Prostaglandins E/*blood | 5 | 55.0 |
*Abortion, Induced | 2 | 9.0 |
Heart Rate/drug effects | 3 | 1.0 |
Stimulation, Chemical | 5 | 1.0 |
Estradiol/analysis | 2 | 10.0 |
Progesterone/analysis | 2 | 10.0 |
Menotropins/pharmacology | 2 | 15.0 |
Prostaglandins A/blood | 2 | 100.0 |
Prostaglandins F/*secretion | 2 | 100.0 |
Uterus/*metabolism | 3 | 6.0 |
6-Ketoprostaglandin F1 alpha | 2 | 100.0 |
Gingiva/*analysis | 2 | 66.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Pregnancy Trimester, Third | 3 | 1.0 |
*Infant, Newborn | 2 | 4.0 |
Chorion/metabolism | 2 | 12.0 |
Placenta/metabolism | 2 | 1.0 |
Fetal Blood/*analysis | 2 | 5.0 |
Injections | 2 | 1.0 |
Injections, Intravenous | 2 | 0.0 |
Ovarian Follicle/*metabolism | 3 | 11.0 |
*Ovulation/drug effects | 2 | 100.0 |
Lung/*metabolism | 2 | 2.0 |
Muscle, Smooth/drug effects | 3 | 15.0 |
Ovum Transport/*drug effects | 2 | 66.0 |
Luteinizing Hormone/pharmacology | 2 | 6.0 |
Pressure | 2 | 1.0 |
Prostaglandins F/analysis/*biosynthesis | 2 | 100.0 |
Models, Biological | 2 | 0.0 |
Depression, Chemical | 2 | 1.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
